Cargando…

Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study

PURPOSE: It has been proved that the gut microbiome is altered in patients with chronic kidney disease. This contributes to chronic inflammation and increases cardiovascular risk and mortality, especially in those undergoing hemodialysis. Phosphate binders may potentially induce changes in their mic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merino-Ribas, Ana, Araujo, Ricardo, Bancu, Ioana, Graterol, Fredzzia, Vergara, Andrea, Noguera-Julian, Marc, Paredes, Roger, Bonal, Jordi, Sampaio-Maia, Benedita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2021
Materias:	Nephrology - Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262763/ https://www.ncbi.nlm.nih.gov/pubmed/34923600 http://dx.doi.org/10.1007/s11255-021-03091-3

Ejemplares similares

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care
por: Rhee, Connie M., et al.
Publicado: (2022)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients
por: Abdelbary, Mohamed M. H., et al.
Publicado: (2022)

Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study
por: Coyne, Daniel W., et al.
Publicado: (2020)

Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide
por: Stavroulopoulos, Aristeidis, et al.
Publicado: (2018)

Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric  Oxyhydroxide
por: Cozzolino, Mario, et al.
Publicado: (2014)

Frail Patient in Hemodialysis: A New Challenge in Nephrology—Incidence in Our Area, Barcelonès Nord and Maresme
por: Bancu, Ioana, et al.
Publicado: (2017)

One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis
por: Kendrick, Jessica, et al.
Publicado: (2019)

Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease
por: Greenbaum, Larry A., et al.
Publicado: (2020)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
por: Coyne, Daniel W., et al.
Publicado: (2017)

Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide
por: Gray, Kathryn, et al.
Publicado: (2019)

The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis
por: Ramos, Rosa, et al.
Publicado: (2020)

Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model
por: Nemoto, Yoshikazu, et al.
Publicado: (2019)

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure
por: Neven, Ellen, et al.
Publicado: (2020)

Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients
por: Shima, Hisato, et al.
Publicado: (2018)

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients
por: Minakuchi, Hitoshi, et al.
Publicado: (2020)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
por: Kendrick, Jessica B, et al.
Publicado: (2022)

Drug–drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects
por: Chong, Edward, et al.
Publicado: (2014)

Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study
por: Ferreira, Aníbal, et al.
Publicado: (2019)

Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells
por: Thiem, Ursula, et al.
Publicado: (2022)

Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study
por: Kalantar-Zadeh, Kamyar, et al.
Publicado: (2019)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis
por: Perez, Luis, et al.
Publicado: (2022)

New Insights Into Diuretic Use to Treat Congestion in the ICU: Beyond Furosemide
por: Escudero, Victor Joaquin, et al.
Publicado: (2022)

Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation
por: Floege, Jürgen, et al.
Publicado: (2020)

A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study
por: Yaguchi, Atsushi, et al.
Publicado: (2019)

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial
por: Thiem, Ursula, et al.
Publicado: (2020)

Cure of Refractory Hypotension in a Hemodialysis Patient
por: Bhatta, Prajjwol D, et al.
Publicado: (2023)

Hemodialysis Catheter-Related Thrombi: A Challenging Patient
por: Abrantes, Catarina, et al.
Publicado: (2020)

Assessment of the Nutritional Status of the Hemodialysis Patients by Anthropometric Measurements
por: Sultan, Sajid, et al.
Publicado: (2021)

Evaluation of hemodialysis vascular access. Perspective from Mexico
por: García-Yañez, Juan C., et al.
Publicado: (2023)

Plant-derived compounds for treating autosomal dominant polycystic kidney disease
por: Zhang, Jieting, et al.
Publicado: (2023)

Hemodialysis Session Duration, Ultrafiltration Rate, Interdialytic Weight Gain and their Association with Albumin in Patients on Intermittent Hemodialysis in a Regional Dialysis Unit: A Cross-sectional Study
por: Rafi Ahmed, Adeel, et al.
Publicado: (2018)

A Rare and Severe Cause of Abdominal Pain in a Hemodialysis Patient
por: Furtado, Teresa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c97dfenahmmn0a4vsas13hj9bi